Open

IMVT Batoclimab Efficacy and Safety

This study aims to test the safety and effectiveness of batoclimab in treating patients with Myasthenia Gravis.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At most visits, blood draw, EKG, questionaries will be asked of the participant. For the entire duration of the study, the willingness to take the study medication as instructed will be required.

Incentives

Parking and milage reimbursement

In-person visits:
23

Phone or online visits:
10

Total length of participation:
1.5 years

Looking for Specific Volunteers

Able to participate:

Generalized Mysathenia Gravis
gMG antibody positive

Not eligible if:

Pregnant, breast feeding or planning to become pregnant during study particpation
Severe or uncontrolled generalized myasthenia gravis

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Vinay Chaudhry
Neurology-Neuromuscular

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System

IRB Number

22-3019

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.